J&J climbs after receiving FDA authorization for surgical robot
JNJ•FDA authorization for Ottava robotic surgical system
Shares of healthcare conglomerate Johnson & Johnson JNJ.N rise 1.1% to $253.19.
The company says the U.S. FDA has granted a marketing authorization for its Ottava robotic surgical system for soft tissue procedures.
Ottava is used across a broad range of general surgery procedures, including bariatric, gastrointestinal, hernia, and abdominal soft-tissue surgeries.
J&J says it will begin a U.S. commercial launch with select customers.
Up to last close, stock up 21% YTD.
